Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Chad M. Robins Sells 99,107 Shares

Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Chad M. Robins sold 99,107 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $8.44, for a total transaction of $836,463.08. Following the completion of the sale, the chief executive officer now directly owns 2,576,701 shares of the company’s stock, valued at approximately $21,747,356.44. This trade represents a 3.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Adaptive Biotechnologies Stock Performance

Shares of ADPT stock opened at $8.27 on Friday. The firm’s 50 day moving average price is $7.20 and its 200-day moving average price is $5.77. Adaptive Biotechnologies Co. has a one year low of $2.28 and a one year high of $8.95. The firm has a market cap of $1.22 billion, a P/E ratio of -7.59 and a beta of 1.50.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.04. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. During the same period last year, the company posted ($0.30) EPS. As a group, research analysts predict that Adaptive Biotechnologies Co. will post -0.94 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Scotiabank increased their price target on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 13th. The Goldman Sachs Group increased their price target on shares of Adaptive Biotechnologies from $5.50 to $7.50 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler restated an “overweight” rating and issued a $11.00 price objective (up from $7.00) on shares of Adaptive Biotechnologies in a report on Thursday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and a consensus price target of $9.10.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of hedge funds have recently added to or reduced their stakes in the business. Impact Partnership Wealth LLC lifted its holdings in Adaptive Biotechnologies by 8.8% during the 4th quarter. Impact Partnership Wealth LLC now owns 19,078 shares of the company’s stock worth $114,000 after buying an additional 1,539 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Adaptive Biotechnologies by 2.7% during the 4th quarter. Russell Investments Group Ltd. now owns 80,994 shares of the company’s stock worth $486,000 after buying an additional 2,163 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Adaptive Biotechnologies by 4.1% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,916 shares of the company’s stock worth $395,000 after buying an additional 2,625 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Adaptive Biotechnologies by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,292 shares of the company’s stock worth $188,000 after buying an additional 2,928 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in Adaptive Biotechnologies by 5.6% during the 4th quarter. MetLife Investment Management LLC now owns 68,976 shares of the company’s stock worth $414,000 after buying an additional 3,650 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.